MedTrace Logo

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

NCT05973903 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-04

No results posted yet for this study

Summary

This will be a prospective, open label, single center, phase I lead-in study of 10 patients to a single arm phase-II study of 37 additional patients to assess the effectiveness of pembrolizumab and lenvatinib combination therapy for recurrent glioblastoma (rGBM) patients wearing TTFields electrodes.

Conditions

Interventions

DRUG

Lenvatinib

Oral Lenvatinib 20 mg once daily

DRUG

Pembrolizumab

intravenous pembrolizumab 200 mg every three weeks

DEVICE

Tumor Treating Fields (TTFields)

TTF extra-dermal scalp electrodes

Sponsors & Collaborators

  • Tel Aviv Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-10-01
Completion
2027-10-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05973903 on ClinicalTrials.gov